COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT03906331
Previous Study | Return to List | Next Study

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03906331
Expanded Access Status : Available
First Posted : April 8, 2019
Last Update Posted : May 21, 2020
Eli Lilly and Company
Information provided by (Responsible Party):
Loxo Oncology, Inc.

Brief Summary:
Expanded access for patients with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial.

Condition or disease Intervention/treatment
Non Small Cell Lung Cancer Medullary Thyroid Cancer Colon Cancer Breast Cancer Pancreatic Cancer Papillary Thyroid Cancer Other Solid Tumors With Evidence of Activating RET Alteration Drug: Selpercatinib

Detailed Description:
N/A for expanded access

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients, Treatment IND/Protocol
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Intervention Details:
  • Drug: Selpercatinib
    Open-label expanded access
    Other Name: LOXO-292

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib

Exclusion Criteria:

  • Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03906331

Layout table for location contacts
Contact: Patient Advocacy 888-406-9574
Contact: There may be multiple sites in this clinical trial 1-877-CTLILLY (877-285-4559) or 1-317-615-4559

Show Show 46 study locations
Sponsors and Collaborators
Loxo Oncology, Inc.
Eli Lilly and Company
Layout table for investigator information
Study Director: JongSeok Kim, MD Eli Lilly and Company
Layout table for additonal information
Responsible Party: Loxo Oncology, Inc. Identifier: NCT03906331    
Other Study ID Numbers: Selpercatinib EAP
Selpercatinib EAP ( Other Identifier: Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company )
First Posted: April 8, 2019    Key Record Dates
Last Update Posted: May 21, 2020
Last Verified: October 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Thyroid Cancer, Papillary
Thyroid Diseases
Neoplasms by Site
Endocrine Gland Neoplasms
Endocrine System Diseases
Head and Neck Neoplasms
Adenocarcinoma, Papillary
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type